TNYA (Tenaya Therapeutics) Short Interest


TNYA Tenaya Therapeutics Inc TNYA
32 GF Score
Price $0.73
! 4 Warning Signs
View Full Analysis

What is Tenaya Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TNYA vs MIST, NRXP, TLSA: Short Interest Comparison

For the Biotechnology subindustry, Tenaya Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tenaya Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Tenaya Therapeutics's Short Interest falls into.


TNYA
32GF Score
Tenaya Therapeutics Inc TNYA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenaya Therapeutics Business Description

Address 171 Oyster Point Boulevard, Suite 500, 5th Floor, South San Francisco, CA, USA, 94080
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
32GF Score

Get the complete analysis for TNYA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price